SHB-02-CD19
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SHB-02-CD19, covering 2026-03-31 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies [Phase 1, Phase 2]